Eli Lilly's Alzheimer's Drug Could Potentially Bring in Billions
Eli Lilly's Alzheimer's drug Solanezumab could add $7.5 billion in peak sales and "supercharge" earnings, Goldman Sachs analyst Jami Rubin said Tuesday as she upgraded the stock on expectations of long-term sales acceleration.
Rubin noted Lilly is highly diversified and not dependent on Solanezumab, an antibody that could act as a neuroprotector for patients with Alzheimer's disease. Without Sola, she sees $12.5 billion in new product sales, representing nearly half of total sales, by 2020.
Rubin noted Lilly is highly diversified and not dependent on Solanezumab, an antibody that could act as a neuroprotector for patients with Alzheimer's disease. Without Sola, she sees $12.5 billion in new product sales, representing nearly half of total sales, by 2020.